Saturday, December 21, 2024

Canada’s Politics and Government News Source Since 1989

Saturday, December 21, 2024 | Latest Paper

Pharmacare, patient groups, and the need for open discourse

Canada needs a universal, national, publicly funded pharmacare program, which would improve drug safety and effectiveness.

Opinion
BY SHARON BATT
February 8, 2021

Opinion | BY SHARON BATT | February 8, 2021

FOLLOW THE HILL TIMES:

Want to make sure your whole office has the full Hill Times experience?

We have team plans available for companies, organizations, classes, Parliament Hill offices and more. Fill out this form and find out if your team is eligible for a discount.

More Opinion

Hundreds of billions in ‘contingent liabilities’ loom large over Canada

OpinionBY TOM FLANAGAN

Justin Trudeau no longer has a mandate to govern, and he doesn’t care

OpinionBY JAKE ENWRIGHT

Canada needs a stable democratic partner in South Korea

OpinionBY MIKE DANAGHER

What Canada needs in its next prime minister

OpinionBY JOSEPH INGRAM

Like it or not, the die is cast

OpinionBY MICHAEL HARRIS

Related Stories

A national pharmacare plan should cover what’s best for patients, not what’s new

OpinionBY COLLEEN FULLER, SHARON BATT

First phase of pharmacare must not ‘create new gaps’ in existing coverage, say lobbyists

NewsBY JESSE CNOCKAERT

Trudeau’s pharmacare plan would likely reduce drug coverage for millions of Canadians

OpinionBY KRISTINA ACRI

Government hostility to biopharmaceutical industry reduces access to innovative drugs

OpinionBY NIGEL RAWSON, JOHN ADAMS

Multi-payer pharmacare will fail Canadians

OpinionBY STEVE MORGAN

A national pharmacare plan should cover what’s best for patients, not what’s new

OpinionBY COLLEEN FULLER, SHARON BATT

Using insulin is always challenging, so access to a broad range of appropriate options is vital.

A national pharmacare plan should cover what’s best for patients, not what’s new

OpinionBY COLLEEN FULLER, SHARON BATT

Using insulin is always challenging, so access to a broad range of appropriate options is vital.

First phase of pharmacare must not ‘create new gaps’ in existing coverage, say lobbyists

NewsBY JESSE CNOCKAERT

Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.

First phase of pharmacare must not ‘create new gaps’ in existing coverage, say lobbyists

NewsBY JESSE CNOCKAERT

Bill C-64 outlines a proposed first phase towards implementation of national universal pharmacare to address accessibility and affordability of prescription drugs and related products.

Trudeau’s pharmacare plan would likely reduce drug coverage for millions of Canadians

OpinionBY KRISTINA ACRI

The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.

Trudeau’s pharmacare plan would likely reduce drug coverage for millions of Canadians

OpinionBY KRISTINA ACRI

The proposed new law would likely prohibit Canadians from purchasing supplemental insurance to cover drugs not covered (or only partially covered) by pharmacare.

Government hostility to biopharmaceutical industry reduces access to innovative drugs

OpinionBY NIGEL RAWSON, JOHN ADAMS

Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.

Government hostility to biopharmaceutical industry reduces access to innovative drugs

OpinionBY NIGEL RAWSON, JOHN ADAMS

Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need new drugs either have their access long delayed, or denied.

Multi-payer pharmacare will fail Canadians

OpinionBY STEVE MORGAN

Private insurers want Canada to embrace a multi-payer pharmacare system without the tools necessary to protect public interests, promote equity, and ensure value.

Multi-payer pharmacare will fail Canadians

OpinionBY STEVE MORGAN

Private insurers want Canada to embrace a multi-payer pharmacare system without the tools necessary to protect public interests, promote equity, and ensure value.